Neogenomics (NEO) Cash from Operations Growth (3y) (2013 - 2026)
Neogenomics (NEO) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 11.33% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -7.30% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | 39.21% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | -11.38% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 11.55% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 20.12% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 24.17% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 5.18% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 8.23% |
| 10 | Neogenomics | 2.42 Bn | 2.28 Bn | 91.88 Mn | 146.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.04% |
| Mar 31, 2026 | 13.77% |
| Dec 31, 2025 | 33.22% |
| Sep 30, 2025 | 36.55% |
| Jun 30, 2025 | 47.30% |
| Mar 31, 2025 | 4.46% |
| Dec 31, 2024 | 35.64% |
| Sep 30, 2024 | 47.21% |
| Jun 30, 2024 | 128.91% |
| Mar 31, 2024 | -139.43% |
| Dec 31, 2023 | 43.77% |
| Sep 30, 2023 | -131.77% |
| Jun 30, 2023 | -41.32% |
| Mar 31, 2023 | -22.33% |
| Dec 31, 2022 | -45.76% |
| Sep 30, 2022 | -42.16% |
| Jun 30, 2022 | -53.26% |
| Mar 31, 2022 | -89.11% |
| Dec 31, 2021 | -48.58% |
| Sep 30, 2021 | -43.04% |